Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy

• Published in: Cardiovascular research 1994-09, Vol.28 (9), p.1360-1365
• Main Authors: Chiu, William C, Kedem, Joseph, Weiss, Harvey R, Tse, James, Cheinberg, Boris V, Scholz, Peter M
• Format: Article
• Language: English
• Subjects: 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors; Animals; aortic stenosis; Aortic Valve Stenosis - metabolism; Biological and medical sciences; cardiac hypertrophy; Cardiovascular system; coronary blood flow; cyclic AMP-phosphodiesterase inhibitor; Disease Models, Animal; Dogs; Hypertrophy, Left Ventricular - metabolism; Medical sciences; Milrinone; Miscellaneous; Myocardial Contraction - drug effects; myocardial oxygen consumption; myocardial work; Myocardium - enzymology; Myocardium - metabolism; Oxygen Consumption - drug effects; Pharmacology. Drug treatments; Phosphodiesterase Inhibitors - pharmacology; Pyridones - pharmacology
• ISSN: 0008-6363; 1755-3245
• DOI: 10.1093/cvr/28.9.1360

Objective: The aim was to test the hypothesis that local myocardial work and O2 consumption would respond differentially to milrinone, a selective cyclic AMP-phosphodiesterase inhibitor, in left ventricular hypertrophy due to differences in myocardial cyclic AMP-phosphodiesterase activity. Methods: The effect of milrinone on regional segment work and regional O2 consumption was measured in 12 open chest anaesthetised dogs with left ventricular hypertrophy induced by valvular aortic stenosis and in 10 age matched control dogs. Regional myocardial work was calculated as the integrated product of instantaneous force development (miniature transducer) and segment shortening (sonomicrometer). Regional O2 consumption was calculated from coronary blood flow (radiolabelled microspheres) and O2 saturations in small regional vessels (microspectrophotometry). Low Km phosphodiesterase activity was assayed by measuring the hydrolysis of radiolabelled cyclic AMP. Results: Milrinone increased left ventricular dP/dtmax by approximately 60-70% in both control [2808(SEM 314) to 4584(660) mm Hg·s−1] and left ventricular hypertrophy [3279(258) to 5589(470) mm Hg·s−1]. Regional work increased significantly in control [612(88) to 955(101) g·mm·min−1], while the increase was not significant in left ventricular hypertrophy [859(139) to 974(172) g·mm·mins−1]. Regional O, consumption increased significantly with milrinone in left ventricular hypertrophy [8.1(1.2) to 13.1(2.4) ml O2min−1·100 g−1], but the increase was not significant in control [6.9(1.2) to 7.4(1.0) ml O2·min−1· g−1] Myocardial stiffness during ejection was increased by milrinone to a significantly greater extent in animals with left ventricular hypertrophy. These effects were not related to differences in cyclic AMP-phosphodiesterase activity between control hearts and hearts with left ventricular hypertrophy [393(45) v 402(36) pmol·mg protein−1·−1]. Conclusions: Differences between the hypertrophied and normal canine myocardium in response to milrinone are either due to altered levels of cyclic AMP production in left ventricular hypertrophy, to effects of milrinone that are unrelated to cyclic AMP-phosphodiesterase inhibition, or to other differences in hypertrophied hearts. The greater stiffness of the myocardium in left ventricular hypertrophy may require a greater energy expenditure to increase the amount of work it performs. Cardiovascular Research 1994;28:1360-1365